Skip Navigation

JNCI Monographs 2001 2001(30):17-21;
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Clark, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clark, G. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute Monographs, No. 30, 17-21, 2001
© 2001 Oxford University Press

Interpreting and Integrating Risk Factors for Patients With Primary Breast Cancer

Gary M. Clark

Correspondence to: Gary M. Clark, Ph.D., Breast Center at Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 (e-mail: gmclark{at}breastcenter.tmc.edu).

The term risk factor has different meanings in different contexts. Some factors may be patient specific (e.g., race, age, socioeconomic status, and environment), while others may be disease specific (e.g., biomarkers measured on tumor specimens, serum, and bone marrow). These factors have several potential clinical uses, including diagnosing a disease or assessing the risk of developing a disease, estimating prognosis for patients diagnosed with a specific disease who receive no therapy, predicting response to a particular therapy, monitoring response to therapy during a treatment course, and identifying targets of opportunity for new therapies. This article focuses on prognostic and predictive biomarkers and provides guidelines for interpreting published reports about these biomarkers. Application of these guidelines to the assessment of micrometastases in bone marrow of patients with breast cancer yields the conclusion that standardized techniques that are sensitive and reproducible for detecting micrometastases are needed before we can evaluate their prognostic significance.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.